Republican former VP Dick Cheney says he will vote for Kamala Harris
Brazil studies raising taxes without lawmaker approval, sources say
Pennsylvania, Arizona and Texas benefit from US funding for Ukraine arms, Pentagon says
Dell, Palantir and Erie Indemnity to join S&P 500
Without astronauts, Boeing's Starliner undocks from space station
Some NFL fans defy host soccer club's preference by wearing green to Packers-Eagles game in Brazil
Alex Morgan leaves women's soccer 'in an amazing place' to focus on expanding her family
By Jonathan Stempel
NEW YORK (Reuters) - The maker of Robitussin settled a consumer lawsuit that claimed its "non-drowsy" cough and flu medicine causes drowsiness, agreeing to pay $4.5 million and remove the "non-drowsy" claim from its packaging and marketing.
A preliminary settlement with Haleon, which was spun off by GSK in July 2022, was filed on Monday in the White Plains, New York, federal court and requires a judge's approval. Haleon denied wrongdoing in agreeing to settle.
Consumers in the proposed class action claimed that GSK and later Haleon misled them by labeling at least 16 Robitussin products that contain the active ingredient dextromethorphan hydrobromide as non-drowsy.
They cited medical research and a 2017 GSK presentation for their claim, and said the Federal Aviation Administration forbids pilots from flying after taking medicine containing the ingredient.
The named plaintiffs, Nancy Calchi of Bloomingburg, New York, and Stacey Papalia of Ossining, New York, said they would not have bought Robitussin products in reliance on the "non-drowsy" claim had they known the truth.
Haleon did not immediately respond to requests for comment. Lawyers for the consumers did not immediately respond to similar requests.
The settlement covers Robitussin purchasers from Feb. 16, 2016 to the present.
Payouts may total $1.50 to $4.75 per claim, depending on the number of claims. As much as $2.05 million, or 46% of the settlement, could go toward legal fees and settlement expenses.
A trial judge dismissed the lawsuit in March 2023, prompting an appeal by the consumers. The appeal was put on hold while the parties negotiated a settlement, court papers show.
The cases are Calchi v GlaxoSmithKline Consumer Healthcare Holdings (US) LLC et al, U.S. District Court, Southern District of New York, No. 22-01341; and Papalia v GlaxoSmithKline Consumer Healthcare Holdings (US) LLC in the same court, No. 22-02630.
(Reporting by Jonathan Stempel in New York; Editing by Aurora Ellis)
